O	0	8	Positive
O	9	16	effects
O	17	19	of
B-intervention	20	31	acupressure
I-intervention	32	37	bands
O	38	46	combined
O	47	51	with
O	52	62	relaxation
O	63	68	music
O	68	69	/
O	69	81	instructions
O	82	84	on
O	85	93	patients
O	94	98	most
O	99	101	at
O	102	106	risk
O	107	110	for
B-condition	111	123	chemotherapy
I-condition	123	124	-
I-condition	124	131	induced
I-condition	132	138	nausea
O	138	139	.

O	140	148	Research
O	149	151	by
O	152	155	our
O	156	161	group
O	162	165	has
O	166	171	shown
O	172	176	that
O	177	188	acupressure
O	189	194	bands
O	195	198	are
O	199	210	efficacious
O	211	213	in
O	214	222	reducing
O	223	235	chemotherapy
O	235	236	-
O	236	243	induced
O	244	250	nausea
O	251	252	(
O	252	255	CIN
O	255	256	)
O	257	260	for
O	261	267	breast
O	268	274	cancer
O	275	283	patients
O	284	287	who
O	288	294	expect
O	295	301	nausea
O	301	302	,
O	303	306	and
O	307	311	that
O	312	317	their
O	318	331	effectiveness
O	332	334	in
O	335	346	controlling
O	347	350	CIN
O	351	354	can
O	355	362	largely
O	363	365	be
O	366	375	accounted
O	376	379	for
O	380	382	by
O	383	391	patients
O	391	392	'
O	393	405	expectations
O	406	408	of
O	409	417	efficacy
O	417	418	,
O	419	420	i
O	420	421	.
O	421	422	e
O	422	423	.
O	423	424	,
O	425	426	a
O	427	434	placebo
O	435	441	effect
O	441	442	.

O	443	446	The
O	447	454	present
O	455	463	research
O	464	472	examined
O	473	475	if
O	476	479	the
O	480	493	effectiveness
O	494	496	of
O	497	508	acupressure
O	509	514	bands
O	515	520	could
O	521	523	be
O	524	532	enhanced
O	533	535	by
O	536	544	boosting
O	545	553	patients
O	553	554	'
O	555	566	expectation
O	567	569	of
O	570	573	the
O	574	579	bands
O	579	580	'
O	581	589	efficacy
O	589	590	.

B-total-participants	591	594	Two
I-total-participants	595	602	hundred
I-total-participants	603	608	forty
I-total-participants	608	609	-
I-total-participants	609	612	two
B-eligibility	613	625	chemotherapy
I-eligibility	625	626	-
I-eligibility	626	628	na
I-eligibility	628	629	Ã¯
I-eligibility	629	631	ve
I-eligibility	632	640	patients
I-eligibility	641	645	with
I-eligibility	646	652	breast
I-eligibility	653	659	cancer
I-eligibility	660	663	who
I-eligibility	664	672	expected
I-eligibility	673	679	nausea
O	680	684	were
O	685	695	randomized
O	695	696	.

O	697	701	Arms
O	702	703	1
O	704	707	and
O	708	709	2
O	710	718	received
O	719	730	acupressure
O	731	736	bands
O	736	737	,
O	738	742	plus
O	743	744	a
O	745	755	relaxation
O	756	759	MP3
O	760	763	and
O	764	771	written
O	772	779	handout
O	780	784	that
O	785	789	were
O	790	796	either
O	797	807	expectancy
O	807	808	-
O	808	817	enhancing
O	818	819	(
O	819	822	arm
O	823	824	1
O	824	825	)
O	826	828	or
O	829	839	expectancy
O	839	840	-
O	840	847	neutral
O	848	849	(
O	849	852	arm
O	853	854	2
O	854	855	)
O	855	856	.

O	857	860	Arm
O	861	862	3
O	863	866	was
O	867	870	the
B-control	871	878	control
I-control	879	886	without
I-control	887	892	bands
O	893	895	or
O	896	899	MP3
O	900	903	and
O	904	912	received
O	913	921	standard
O	922	926	care
O	926	927	.

O	928	931	All
O	932	944	participants
O	945	953	received
O	954	963	guideline
O	963	964	-
O	964	973	specified
O	974	985	antiemetics
O	985	986	.

B-outcome	987	991	Peak
I-outcome	992	995	CIN
O	996	999	for
O	1000	1004	arms
O	1005	1006	1
O	1006	1007	,
O	1008	1009	2
O	1009	1010	,
O	1011	1014	and
O	1015	1016	3
O	1017	1019	on
O	1020	1021	a
O	1022	1023	1
O	1023	1024	-
O	1024	1025	7
O	1026	1031	scale
O	1032	1035	was
B-iv-cont-mean	1036	1037	3
I-iv-cont-mean	1037	1038	.
I-iv-cont-mean	1038	1040	52
O	1040	1041	,
B-iv-cont-mean	1042	1043	3
I-iv-cont-mean	1043	1044	.
I-iv-cont-mean	1044	1046	55
O	1046	1047	,
O	1048	1051	and
B-cv-cont-mean	1052	1053	3
I-cv-cont-mean	1053	1054	.
I-cv-cont-mean	1054	1056	87
O	1056	1057	,
O	1058	1070	respectively
O	1071	1072	(
O	1072	1073	p
O	1074	1075	=
O	1076	1077	0
O	1077	1078	.
O	1078	1080	46
O	1080	1081	)
O	1081	1082	.

O	1083	1090	Because
O	1091	1093	no
O	1094	1105	differences
O	1106	1110	were
O	1111	1119	observed
O	1120	1127	between
O	1128	1132	arms
O	1133	1134	1
O	1135	1138	and
O	1139	1140	2
O	1141	1142	(
O	1142	1149	primary
O	1150	1158	analysis
O	1158	1159	)
O	1159	1160	,
O	1161	1163	we
O	1164	1172	combined
O	1173	1178	these
O	1179	1182	two
O	1183	1187	arms
O	1188	1189	(
O	1189	1201	intervention
O	1201	1202	)
O	1203	1206	and
O	1207	1215	compared
O	1216	1220	them
O	1221	1223	to
O	1224	1232	controls
O	1233	1236	for
O	1237	1240	the
O	1241	1250	following
O	1251	1259	analyses
O	1259	1260	.

O	1261	1262	A
O	1263	1274	significant
O	1275	1286	interaction
O	1287	1290	was
O	1291	1296	found
O	1297	1304	between
O	1305	1317	intervention
O	1317	1318	/
O	1318	1325	control
O	1326	1329	and
O	1330	1339	receiving
O	1340	1351	doxorubicin
O	1351	1352	-
O	1352	1357	based
O	1358	1370	chemotherapy
O	1371	1372	(
O	1372	1375	yes
O	1375	1376	/
O	1376	1378	no
O	1378	1379	)
O	1380	1383	and
B-outcome	1384	1387	pre
I-outcome	1387	1388	-
I-outcome	1388	1397	treatment
I-outcome	1398	1405	anxiety
O	1406	1407	(
O	1407	1411	high
O	1411	1412	/
O	1412	1415	low
O	1415	1416	)
O	1416	1417	.

O	1418	1430	Intervention
O	1431	1439	patients
O	1440	1449	receiving
O	1450	1461	doxorubicin
O	1462	1465	had
O	1466	1471	lower
B-outcome	1472	1476	peak
I-outcome	1477	1480	CIN
O	1481	1485	than
O	1486	1494	controls
O	1495	1496	(
B-iv-cont-mean	1496	1497	3
I-iv-cont-mean	1497	1498	.
I-iv-cont-mean	1498	1500	62
O	1501	1503	vs
O	1503	1504	.
B-cv-cont-mean	1505	1506	4
I-cv-cont-mean	1506	1507	.
I-cv-cont-mean	1507	1509	38
O	1509	1510	;
O	1511	1512	p
O	1513	1514	=
O	1515	1516	0
O	1516	1517	.
O	1517	1519	02
O	1519	1520	)
O	1520	1521	.

O	1522	1531	Similarly
O	1531	1532	,
O	1533	1545	intervention
O	1546	1554	patients
O	1555	1559	with
O	1560	1564	high
O	1565	1568	pre
O	1568	1569	-
O	1569	1578	treatment
O	1579	1586	anxiety
O	1587	1590	had
O	1591	1592	a
O	1593	1598	lower
B-outcome	1599	1603	peak
I-outcome	1604	1607	CIN
O	1608	1612	than
O	1613	1621	controls
O	1622	1623	(
B-iv-cont-mean	1623	1624	3
I-iv-cont-mean	1624	1625	.
I-iv-cont-mean	1625	1627	62
O	1628	1630	vs
O	1630	1631	.
B-cv-cont-mean	1632	1633	4
I-cv-cont-mean	1633	1634	.
I-cv-cont-mean	1634	1636	62
O	1636	1637	;
O	1638	1639	p
O	1640	1641	=
O	1642	1643	0
O	1643	1644	.
O	1644	1646	01
O	1646	1647	)
O	1647	1648	.

O	1649	1651	In
O	1652	1658	breast
O	1659	1665	cancer
O	1666	1674	patients
O	1675	1685	undergoing
O	1686	1698	chemotherapy
O	1699	1702	and
O	1703	1709	having
O	1710	1714	high
O	1715	1718	CIN
O	1719	1730	expectation
O	1730	1731	,
O	1732	1743	acupressure
O	1744	1749	bands
O	1750	1758	combined
O	1759	1763	with
O	1764	1765	a
O	1766	1776	relaxation
O	1777	1786	recording
O	1787	1791	were
O	1792	1801	effective
O	1802	1804	in
O	1805	1813	reducing
O	1814	1817	CIN
O	1818	1821	for
O	1822	1830	patients
O	1831	1834	who
O	1835	1843	received
O	1844	1855	doxorubicin
O	1856	1858	or
O	1859	1862	had
O	1863	1867	high
O	1868	1875	anxiety
O	1875	1876	.
